Corticotropin-releasing hormone (CRH) and growth hormone-releasing hormone (GHRH), primarily characterized as neuroregulators of the hypothalamic-pituitary-adrenal axis, directly influence tissue-specific receptor-systems for CRH and GHRH in the endocrine pancreas. Here, we demonstrate the expression of mRNA for CRH and CRH-receptor type 1 (CRHR1) and of protein for CRHR1 in rat and human pancreatic islets and rat insulinoma cells. Activation of CRHR1 and GHRH-receptor significantly increased cell proliferation and reduced cell apoptosis. CRH stimulated both cellular content and release of insulin in rat islet and insulinoma cells. At the ultrastructural level, CRHR1 stimulation revealed a more active metabolic state with enlarged mitochondria. Moreover, glucocorticoids that promote glucose production are balanced by both 11b-hydroxysteroid dehydrogenase (11β-HSD) isoforms; 11β-HSDtype-1 and 11β-HSD-type-2. We demonstrated expression of mRNA for 11β-HSD-1 and 11β-HSD-2 and protein for 11β-HSD-1 in rat and human pancreatic islets and insulinoma cells. Quantitative real-time PCR revealed that stimulation of CRHR1 and GHRHreceptor affects the metabolism of insulinoma cells by downregulating 11β-HSD-1 and up-regulating 11β-HSD-2. The 11β-HSD enzyme activity was analyzed by measuring the production of cortisol from cortisone. Similarly, activation of CRHR1 resulted in reduced cortisol levels, indicating either decreased 11β-HSD-1 enzyme activity or increased 11β-HSD-2 enzyme activity; thus, activation of CRHR1 alters the glucocorticoid balance toward the inactive form. These data indicate that functional receptor systems for hypothalamic-releasing hormone agonists exist within the endocrine pancreas and influence synthesis of insulin and the pancreatic glucocorticoid shuttle. Agonists of CRHR1 and GHRH-receptor, therefore, may play an important role as novel therapeutic tools in the treatment of diabetes mellitus.
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islet proliferation | regenerative therapy | metabolic syndrome R eceptor systems for the corticotropin-releasing hormone (CRH) and the growth hormone-releasing hormone (GHRH) are central regulators of the hypothalamic-pituitaryadrenal axis (HPA-axis). There is, however, increasing evidence for the presence of tissue-specific receptor systems for CRH and GHRH in several tissues involved in the regulation of immune and cardiovascular systems and energy homeostasis (1) (2) (3) (4) (5) . Recently, a functional CRH receptor system expressing both CRHreceptors type 1 and type 2 (CRHR1 and CRHR2) was described in the endocrine pancreas (6, 7) . The CRH receptors belong, together with the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide GIP receptor (GIPR), to the family of class B G protein-coupled receptors (6) . Activation of CRHR1 by CRH has been demonstrated to stimulate Ca 2+ influx and to increase intracellular Ca 2+ concentrations in rat pancreatic islets (8, 9) and to stimulate exocytosis of insulin containing granules in mouse pancreatic β-cells (6) . In addition, CRH-induced insulin release could be enhanced by coincubation with vasopressin, suggesting complex mechanisms of insulin release in pancreatic islets (10) . Therefore, a functional CRH-receptor system within the endocrine pancreas, which mediates insulin secretion, may be important in hypoglycemic episodes occurring in stress-related situations or disorders. Circulating levels of CRH correlate well with stressful situations or situations of disturbed adrenal steroidogenesis, such as pregnancy, psoriasis, Addison disease, inflammation, and bleeding (11) (12) (13) , and therefore might influence insulin secretion in these situations. Moreover, CRH-mediated stimulation of insulin secretion through the preferentially activated CRHR1 seems to occur predominantly during intermediate to high ambient glucose (6) . This finding may suggest a nutrition-or foodrelated regulation of insulin release similar to the incretins stimulating the GLP-1R and GIPR in pancreatic islets (7) . Furthermore, recent evidence suggests that activation of CRHR1 initiates MAPK-signaling (14) and leads to proliferation of rat neonatal β-cells, suggesting a possible beneficial role for CRH in augmentation of β-cell mass (6) . CRHR1 of the anterior pituitary provides a major target in the regulation of circulating glucocorticoids (GC) levels, which induce various features of the metabolic syndrome, including the impairment of β-cell function and of insulin resistance (15, 16) . GCs mediate their effects through the specific intracellular GC receptor (GR) present in almost all cell types, including pancreatic β-cells (17) . Recently, GCs have been shown to inhibit the expression of CRHR1 and incretin receptors on pancreatic islets (7) . The available levels of the biologically active GCs are regulated by 11β-hydroxysteroid dehydrogenase (11β-HSD). Two different isoenzymes of 11β-HSD have been characterized; 11β-HSD type 1 and type 2 (11β-HSD-1 and 11β-HSD-2) (18). Isoenzyme 11β-HSD-1 interconverts active GC (corticosterone in rodents, cortisol in humans) to their metabolites (11-dehydrocorticosterone in rodents, cortisone in humans). There is evidence for an increased expression and activity of the type-1 isoenzyme in diabetic islets, which leads to increased local tissue concentrations of active GCs in diabetic rodents (19) . Moreover, it has been shown that selective inhibition of 11β-HSD-1 decreases blood glucose concentrations in hyperglycemic mice (20) . The type-2 isoenzyme converts active GCs to their inactive form, thus protecting the glucocorticoid and mineralcorticoid receptor against occupancy by active GCs, thereby leading to insulin resistance and diabetes (21) . The inhibition of 11β-HSD activity by carbenoxolone and resultant reduction in intracellular cortisol concentrations produced an increased insulin sensitivity and decreased glucose production (22) . Therefore, inhibition of 11β-HSD-1 expression and activity may provide a previously unexplored therapeutic tool of an antidiabetic drug therapy.
Based on these findings, we addressed several questions in this study regarding a tissue-specific receptor system for hypothalamic-releasing hormones in the endocrine pancreas. Is there a functional CRH/CRHR system in human pancreatic islets influencing metabolic activity of pancreatic β-cells? Does CRH contribute to enhanced islet mass through an antiapoptotic or proliferative effect? How does the effect of CRH compare with that of the GHRH-agonist JI-36, recently identified as a strong effector for survival and proliferation of pancreatic islets (5)? Which role for regulating the intracellular cortisone/cortisol conversion and maintaining an adequate exposure of GC is played by the 11β-HSD enzyme system in pancreatic islets? Finally, most importantly, is there a protective mechanism allowing CRH to influence insulin synthesis and augmentation of β-cell mass in the presence of elevated GC levels?
Results

CRH and CRHR1 Are Expressed in Insulinoma Cells and in Rat and
Human Pancreatic Islets. RT-PCR analysis revealed the expression of CRH and CRHR1 mRNA in rat insulinoma (INS)-1 cells, primary rat islets, and primary human islets (Fig. 1A) . Western blot analysis verified the expression of CRHR1 protein (55 kDa) in INS-1 cells, rat islets and human islets (Fig. 1B) . Immunohistochemical analysis demonstrated CRHR1 expression in rat islets (Fig. 1C) and INS-1 cells (Fig. 1D) . Pancreatic β-cells in rat islets were identified by immunostaining for insulin and nuclei of INS-1 cells were stained with DAPI.
Ultrastructural Analysis of Insulinoma Cells Cultured with Hypothalamic
Peptides. INS-1 cells under normal culture conditions were characterized by insulin-containing secretory granules in the cytoplasm ( Fig. 2A) . Treatment of INS-1 cells with 10 −10 M CRH resulted in a reduction of secretory granules and in enlargement of mitochondria (Fig. 2B) antagonist astressin (10 −6 M), partly abrogated the antiapoptotic and proliferative effects. The GHRH-agonist JI-36 was applied as a positive control because of its antiapoptotic and proliferative effect on INS-1 cells (5). Stimulation of GHRH receptor (GHRH-R) reduced apoptosis by 21.5 ± 4.9% and increased proliferation by 44.0 ± 11.5%. Effects of JI-36 could be completely blocked by the GHRH-antagonist MIA-602. However, cultivation of INS-1 cells with CRH in combination with JI-36 resulted in an antiapoptotic and a slight proliferative effect. Because CRH dose-dependently increased cell proliferation and conversely decreased the rate of apoptosis in INS-1 cells with a maximum effect at 10 −10 M, CRH was used at 10 −10 M in all following experiments. Thus, the effects of CRH on proliferation and apoptosis were evaluated at concentrations of 10 −6 M to 10
M and incubation times of 24, 48, 72, and 96 h; however, only the concentrations of 10 −9 M and 10 −10 M caused significant effects compared with control cells. DMSO as solvent control had no effect on proliferation or apoptosis. In further support of the effects of CRH on the endocrine pancreas, we identified by immunohistochemical staining decreased number of pancreatic islets in CRH-negative (CRH −/− ) mice (Fig. 3C ) compared with wild-type mice (Fig. 3D) . Moreover, serum insulin levels were also lower in the CRH −/− mice.
Stimulation of CRHR1 Leads to Glucose-Stimulated Insulin Secretion in Insulinoma Cells and Rat Islets. Functional testing of INS-1 cells was performed by measuring glucose-stimulated insulin secretion and insulin synthesis (Fig. 4) . INS-1 cells and rat islets were exposed to 10 −10 M CRH for 24 and 48 h before glucose stimulation. At basal glucose concentration (3.3 mM), INS-1 cells and rat islets treated with CRH released insulin into the culture media at similar rates as untreated controls. Upon stimulation with high glucose (16.7 mM), insulin release from INS-1 cells, treated and untreated with CRH, was significantly increased by 3.5-and 3.7-fold, respectively, relative to basal glucose concentration (Fig. 4A) . Treatment with CRH, however, resulted in 63% increase in total insulin content compared with untreated INS-1 cells (Fig. 4B ). This effect of CRH on the insulinoma cell line, INS-1, was reproduced in primary rat islet cells. Rat islets, CRH-treated and untreated, responded to high glucose with 
of CRHtreated and untreated cells, respectively (n = 3). (B) CRH treatment of INS-1 cells resulted in an increased amount of total insulin (cellular insulin content + released insulin) by 63% compared with untreated INS-1 cells (n = 3). (C)
Rat pancreatic islets revealed a stimulation index of 6.0 and 5.3 of CRH treated and untreated islets, respectively (n = 3). (D) However, rat islets cultured with CRH resulted in an increased amount of total insulin by 40% compared with untreated rat pancreatic islets (n = 3). (*P < 0.05; **P < 0.01; ***P < 0.001).
a stimulation indices of 6.0 and 5.3, respectively (Fig. 4C) . However, culturing rat pancreatic islets with CRH resulted in an increase of total insulin by ∼40% compared with untreated islets (Fig. 4D) . At basal glucose concentrations, total insulin of rat islets treated with CRH was 10.72 ± 2.16 ng/mL. In contrast, control rat islets contained 5.17 ± 1.43 ng/mL of insulin. Upon stimulation with high glucose, treatment with CRH resulted in 25.05 ± 1.56 ng/mL total insulin compared with control islets, which contained 17.87 ± 0.96 ng/mL insulin. Overall, pretreatment with CRH resulted in enhanced total insulin production, thus contributing to the restoration of normoglycemia.
11β-HSD-1 and 11β-HSD-2 Are Expressed in Insulinoma Cells and in Rat and Human Pancreatic Islets. RT-PCR analysis revealed mRNA expression of 11β-HSD-1 and 11β-HSD-2 in rat INS-1 cells, primary rat islets and primary human islets (Fig. 5A) . Western blot analysis documented the protein expression of 11β-HSD-1 (35 kDa) in INS-1 cells, rat islets, and human islets (Fig. 5B) . In addition, the 11β-HSD-1 protein was detected by immunohistochemical staining in human pancreatic islets (Fig. 5C ), rat pancreatic islets (Fig. 5D) , and INS-1 cells (Fig. 5E) . To confirm the localization of 11β-HSD-1 to pancreatic β-cells, costaining for insulin was performed. Microscopic analysis revealed that all insulin-positive cells stained for 11β-HSD-1. were reduced after 24 and 72 h by 23.3% and 56.9%, respectively, in comparison with untreated INS-1 cells. Cultivation with the GHRH-agonist JI-36 for 72 h revealed a reduced mRNA expression for 11β-HSD-1 by 35.4% in contrast to control. Combination of both hypothalamic-releasing hormone agonists decreased the expression level by 86.2% (Fig. 6A) . Furthermore, treatment with CRH resulted in increased mRNA expression for 11β-HSD-2 by 55.9% and 16.1% of cells cultured for 24 and 72 h, respectively (Fig. 6B) 6C) . DMSO as solvent control had no effect on cortisol levels.
Discussion
Hypothalamic-pituitary regulation of the endocrine pancreas was proposed by the pioneering work of Bernardo Houssay more than half century ago (23) . However, only now is a better understanding is emerging of the complex interaction of hypothalamic-releasing hormones and their input from neuronal networks. Thus, we are beginning to understand the intricate communication between the neuroendocrine stress system and the metabolic regulation of energy expenditure, insulin secretion, and glucose homeostasis, which involves multiple hormones, including at least two hypothalamic hormones. For example, we have previously shown that an agonistic analog of GHRH promoted the proliferation and survival of pancreatic β-cell islets (5). In collaborative studies in 1984, one of the authors (A.V.S.) participated in the demonstration of immunoreactive CRH in the endocrine pancreas (24), although its functions were then unknown. Recently, Huising et al. (6) showed that CRH receptors, expressed on pancreatic β-cells, promote β-cell proliferation and potentiate insulin secretion.
The findings of our present study support the existence of a functionally relevant receptor system for CRH and GHRH in both rodent and human pancreatic islet cells. In addition to stimulating β-cell proliferation and insulin synthesis in a glucosedependent manner, CRH increases viability of β-cells and reduces apoptosis in a dose-dependent manner. This effect was comparable in magnitude to the effect of GHRH agonists previously demonstrated in vitro and in vivo (5) . The proliferative and antiapoptotic effect was partially reversed by the CRH-antagonist astressin. Furthermore, in vivo studies have shown that mice with genetic CRH deficiency had lower islet cell numbers, supporting our in vitro findings. The CRH-deficient mice had reduced serum insulin levels, as indicated in a previous report (25) . These results raise the possibility for a significant role of CRH in pancreas development. This finding may provide a protective mechanism preventing GC-induced cell death and impairment of β-cell function. In addition to its primary action on the pituitary, CRH has been implicated in the regulation of many extrapituitary cell systems. As examples, the skin and also adipose tissue seem to possess a complete and functional local CRH/CRHR system (4, 26) .
The capacity of CRH to induce insulin secretion and cell proliferation, even as enhancing the viability of β-cells and decreasing programmed cell death, may suggest a potential therapeutic use for agonists of CRHR1 in patients with diabetes. At the level of the pituitary, however, activation of CRHR1 by CRH leads to stimulation of adrenocorticotropic hormone-secretion and GC release from the adrenal cortex. GCs mediate all features of the metabolic syndrome by inducing fat cell maturation and obesity, as well as insulin resistance in peripheral tissues. More recently, it became evident that GCs also have direct impact on β-cell function (7). Thus, overexpression of the GR and GR-signaling leads to an increased apoptotic rate, and exposure of patients to GCs results in the inhibition of several parameters of β-cell function. These parameters include both clinical and model-based parameters of β-cell function based on calculations of glucose, insulin, and c-peptide concentrations in serum obtained during standardized meal tests, before and during steroid treatment (27). These findings are in accordance with the observation that patients who receive GCs following islet transplantation will have the benefits of immunoprotection and immune suppression, but will also suffer from the diabetogenic effects of GCs, which include β-cell impairment. Consistent with this finding, GCs have recently been shown to significantly inhibit the expression of incretin receptors and CRHR1 (7) . Our data raise the possibility that the direct actions of CRH on the pancreatic islet cells, possibly as part of a local stress-response system, may have beneficial effects, particularly in states of increased systemic GC levels. In recent years it has, however, become clear, that human metabolic make up includes an enzyme system providing protection from locally high active GC levels based on the differential regulation of the 11β-HSD enzyme system. Currently, selective 11β-HSD-1 inhibitors, which allow the reduction of local GC concentrations by blocking the conversion of cortisone to cortisol, are being applied in clinical trials as a new therapeutic strategy for the treatment of the metabolic syndrome (28, 29) . It has been shown that 11β-HSD-1 mediates GC activation and insulin release in pancreatic islets (30) . A classic blocker of the 11β-HSD system, carbenoxolone, reverses the inhibition of insulin release (22) . Furthermore, increased expression and activity of 11β-HSD occurs in diabetic islets (19) . A down-regulation of 11β-HSD activity by CRH has been previously shown in adipose tissue (31) .
In the present article, we show that rodent and human pancreatic islets include a tissue-specific 11β-HSD enzyme system that is affected by the pancreatic CRH receptor and the GHRH-R system. The endocrine pancreas expresses both type 1 and type 2 enzymes of the 11β-HSD system. Moreover, CRH, through CRHR1, and agonist JI-36, through the GHRH-R, increased the mRNA expression of 11β-HSD-2 while decreasing the mRNA expression of 11β-HSD-1. Consistent with these findings, stimulation of CRHR1 reduced the active GC levels, demonstrating a reduced enzyme activity for 11β-HSD-1 or an increased enzyme activity for 11β-HSD-2. Ultrastructural analysis of insulinoma cells treated with CRH revealed a reduced number of insulin-containing secretory granules and enlarged mitochondria, demonstrating an increased insulin turnover and metabolic activity in these cells. Therefore, regulation of the pancreatic 11β-HSD enzyme system by hypothalamic-releasing hormone agonists may protect the pancreatic islets against the increased GC levels present in diabetic patients. Moreover, it may provide a mechanistic link between the neuroendocrine stress system and islet integrity. This regulation may also produce a mechanism to maintain the beneficial effects of pancreatic CRHR1 or GHRH-R activation on insulin secretion and islet mass in the presence of an activated HPA-axis and the corresponding rise in GC levels.
Materials and Methods
Animals. Housing and care of CRH −/− and wild-type mice were according to National Institutes of Health and European Union guidelines. Mice were kept at a 12-h light-dark cycle and had ad libitum access to standard chow diet (Harlan; Rodent Diet 2018) and water. The CRH −/− mouse line was generated as previously described (32) . CRH −/− mice were raised in C57/Bl6 background and were obtained by crossing of heterozygous strains; their wild-type littermates, CRH +/+ , were used as controls. The genotype of every animal was established by PCR, as previously described. All procedures were approved by the Animal Care and Use Committee of the Biomedical Research Foundation of the Academy of Athens. Serum insulin was measured using an RIA kit (Millipore) according to the manufacturer's instructions. Adult mice (2-4 mo old) were anesthetized and pancreata were dissected in cold PBS, fixed at 4°C for 4 h, dehydrated, and paraffinized.
Rat INS-1 Insulinoma Cells. Rat INS-1 cells were cultured in RPMI medium 1640 (PAA) supplemented with 2 mM L-glutamine, 10% FBS, 1 mM Na-Pyruvate, 50 μM 2-mercaptoethanol, and 100 U/mL penicillin-streptomycin (Gibco) in a humidified 5% CO 2 /95% O 2 atmosphere at 37°C. Fresh medium was added every second day to the culture flasks, cells were passaged once per week.
Isolation of Rat and Human Pancreatic Islets. Pancreatic islets were isolated as previously described (5) . Purified rat islets were maintained in culture media (CMRL 1066; Mediatech) supplemented with 10% FBS at 37°C in a 5% CO 2 incubator. Human islets were cultured at 37°C in a 5% CO 2 incubator in CMRL 1066 (Mediatech) containing 2.5% human serum albumin. Volume and purity were determined by microscopic sizing after staining with dithizone (Sigma-Aldrich).
Chemicals. CRH was purchased from Ferring, dissolved in DMSO, and used at a concentration of 10 −6 M -10 −12 M. The CRH-antagonist astressin was purchased from Bachem, dissolved in DMSO, and used at a final concentration of 10 −6 M. The GHRH-agonist Jl-36, and GHRH-antagonist MIA-602 were synthesized in the A.V.S. laboratory and used at a concentration of 10 −6 M. glucose or 16.7 mM glucose, and cells were incubated for 1 h at 37°. Supernatant was collected and cells were lysed by 0.15% HCl. Secreted insulin and cellular insulin content was measured by RIA using the rat insulin RIA kit (Millipore). Secreted insulin values were normalized to total insulin. Stimulation index reflects the fold-change of insulin release under basal glucose condition compared with high-glucose conditions. For details of quantitative real-time PCR, Western blot analysis, immunohistochemistry and immunofluorescence, electron microscopy, cell apoptosis assay, cell proliferation assay, 11β-HSD activity assay, statistical analysis, and RNA isolation and RT-PCR, see SI Text. For primers used in expression analysis, see Table S1 .
